Clinical Monograph: Shortec 5 mg (Oxycodone Hydrochloride Immediate-Release)

1. Classification and Chemical Overview

Oxycodone is a semi-synthetic phenanthrene-derivative opioid agonist synthesized from the opium alkaloid thebaine. Chemically designated as $(5\alpha ,14\alpha )$-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride. Under the Anatomical Therapeutic Chemical (ATC) system, oxycodone is indexed under N02AA05.

• Product Context: Shortec is an international brand-name formulation of immediate-release oxycodone (commonly manufactured by Martindale Pharma). The low 5 mg strength represents a versatile starting dose or rescue medication unit used for titration or breakthrough pain management.

• Controlled Status: Strictly regulated as a Prescription Only Medicine (POM) and a Schedule II Controlled Substance (or Class A / Schedule 2 Controlled Drug internationally) due to its extremely high potential for abuse, physical dependence, respiratory depression, and fatal overdose liability.

2. Mechanism of Action and Pharmacodynamics

Oxycodone exerts its primary analgesic and physiological effects through high-affinity interactions with central opioid receptors:

• $\mu$-Opioid Receptor Agonism: Acts as a primary agonist predominantly at $\mu$-opioid ($\text{MOR}$) receptors, and to a lesser extent at $\kappa$ ($\text{KOR}$) receptors in the central nervous system and gastrointestinal tract.

• Hyperpolarization & Inhibition: Activation of $\mu$ receptors inhibits adenylate cyclase, closes voltage-gated calcium channels (reducing presynaptic neurotransmitter release), and opens potassium channels (hyperpolarizing postsynaptic neurons).

• Immediate-Release Profile: Designed for rapid dissolution and absorption, providing a swift onset of analgesia to manage acute pain flares or rapid-onset pain episodes.

3. Approved Clinical Indications and Dosing Scope

Licensing for Shortec includes:

• Moderate to Severe Acute Pain: Management of acute moderate-to-severe pain requiring opioid-level intervention (such as post-operative pain or acute injury).

• Breakthrough Pain: Utilization as a rapid-onset rescue medication for patients with chronic pain experiencing breakthrough pain episodes alongside baseline extended-release opioid therapy.

Dosing & Administration Regimen:

• Individualized Titration: Dosage must be individualized based on pain severity, prior opioid exposure, and patient age. While 5 mg is a standard starting or rescue dose, caution is required in opioid-naive individuals.

• Dosing Frequency: Administered orally as needed, typically every 4 to 6 hours for immediate-release preparations.

• Administration Precautions: Unlike modified-release formulations, immediate-release capsules or tablets are designed for rapid systemic delivery; however, tampering or altering capsule contents for non-oral routes carries extreme overdose risks.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Rapidly and almost completely absorbed following oral administration, yielding high oral bioavailability (approximately 60% to 87%). Peak plasma concentrations (Cmax​) occur swiftly within 1 to 1.5 hours post-dose.

• Distribution: Rapidly distributes into skeletal muscle, liver, intestinal tract, lungs, and cerebrospinal fluid. Plasma protein binding is moderate (~45%). Crosses the blood-brain barrier and placenta.

• Biotransformation: Extensively metabolized in the liver via Cytochrome P450 enzymes (CYP3A4 y CYP2D6):

  • Demethylated via CYP3A4 into noroxycodone (major inactive metabolite).

  • Demethylated via CYP2D6 into oxymorphone (an active metabolite with potent $\mu$-opioid affinity, though present in low plasma concentrations).

• Elimination: Excreted primarily via the kidneys in urine as unchanged drug and inactive conjugates. The terminal elimination half-life of immediate-release oxycodone averages 3 to 4 hours.

5. Physiological Effects and Adverse Event Spectrum

Oxycodone depresses central nervous system functions, suppresses respiratory drive, and inhibits gastrointestinal propulsion.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Constipation, somnolence, dizziness, nausea, vomiting, headache, pruritus, asthenia.

• Common ($\ge 1/100$ to $<1/10$): Dry mouth, abdominal pain, dyspepsia, diarrhea, sweating, anxiety, confusion, insomnia, urinary retention, rash.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Dysphoria, hallucinations, agitation, visual disturbances, bronchospasm, biliary tract spasm, flushing, orthostatic hypotension.

• Rare / Severe (<1/1,000): Severe respiratory depression, apnea, circulatory depression, anaphylactoid reactions, paralytic ileus, toxic megacolon, opioid-induced hyperalgesia, seizures.

6. Contraindications, Drug Interactions, and Clinical Precautions

Contraindicaciones

• Known hypersensitivity to oxycodone or other phenanthrene alkaloids.

• Acute respiratory depression, severe chronic obstructive pulmonary disease (COPD), or acute asthma attacks.

• Paralytic ileus or suspected surgical acute abdomen.

• Moderate-to-severe hepatic impairment.

• Concurrent administration with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of their cessation.

Key Drug Interactions

• CNS Depressants, Alcohol, & Benzodiazepines: Co-administration produces profound, synergistic central nervous system and respiratory depression, significantly elevating the risk of coma and fatal overdose.

• Strong CYP3A4 Inhibitors or Inducers (e.g., Ketoconazole, Macrolide Antibiotics, Rifampicin): Inhibitors can escalate oxycodone plasma concentrations and toxicity risks, whereas inducers can accelerate clearance and reduce analgesic efficacy.

• Serotonergic Agents: Co-administration with other serotonergic medications can increase the risk of serotonin syndrome.

Clinical Precautions and Monitoring

• Boxed Warning (Addiction, Abuse, and Misuse; Life-Threatening Respiratory Depression): Shortec exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing and monitor all patients regularly. Serious, life-threatening, or fatal respiratory depression can occur.

• Neonatal Opioid Withdrawal Syndrome: Long-term maternal use of oxycodone during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated.